BC Platforms Partners with Proteus Genomics to realize precision medicine by combining genomic analysis and data handling technology

BC Platforms, a world leader in genomic data management and analytics, announced that it has partnered with Proteus Genomics, a clinical reference lab specializing in pharmacogenomics, to streamline genomic and healthcare data integration. This new approach will optimize Proteus Genomics’ handling of genomic data, taking one step further towards the implementation of precision medicine.

With over 20 years of experience in managing genomic data, BC Platforms has developed a unique technology capable of downstream, end to end analysis of thousands of genomes per day, using either genotype arrays or next generation sequencing. Applying this to Proteus’s efficient system to harvest more genetic data and streamline reporting and handling from Illumina devices will reduce downstream costs. It will help sort data and indicate genetically corresponding patient treatments, in order to minimize adverse drug events and unnecessary expensive procedures. This further extends BC Platform’s world class precision medicine solution, both in cloud and on-premise.

In the US, adverse drug events are the fourth leading cause of death, costing the healthcare industry more than $3.5 billion annually. This cost is significantly reduced with genotyping and next generation sequencing technology, which provides genomic context thereby helping to avoid adverse effects. Additionally, as healthcare in the clinic shifts from a one-for-all approach into personalized care plans, physicians are seeking to develop more targeted therapies for their patients. By combining pharmacology and genomics information through pharmacogenetics, it is possible to provide contextual information that enables clinicians to develop effective, safe medications and doses that are tailored to a patient’s genetic makeup.

Tero Silvola, CEO of BC Platforms commented, “Together, BC Platforms and Proteus Genomics will help advance precision medicine through our streamlined approach to manage data from sequencing machines all the way through to clinical applications. We expect these organized genomics analyses will help create clear, actionable insights to improve patient care and reduce treatment costs.”

Ben Williams, CEO of Proteus Genomics, commented, “We are delighted to be collaborating with BC platforms, a leader in the space of genomic data management and analysis.  We believe this partnership will play a critical role in continuing to expand the delivery of clinically actionable precision medicine.”